IP Library Granted Patent US 12,109,206
Granted Patent B2
US 12,109,206 · App. 17/872,575 · Granted Oct 8, 2024

Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Inventors: Eric A. Marcotulli (New York, NY); Daniel A. Alminana (New York, NY); Paul M. Bowen (Newton, MA)
Assignee: Elysium Health, Inc.
A61K31/455A61K8/368A61K8/675A61K9/0053A61K9/4866A61K31/09A61K31/706A61P17/00A61Q19/004A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,109,206
App. No.
17/872,575
Granted
Oct 8, 2024
Kind
B2
Abstract

Compositions containing a combination of nicotinamide riboside and pterostilbene for treating skin disorders, and methods of treating skin disorders using these compositions and their equivalents are described. The skin disorders that are treated using these compositions or methods include sun exposure-related skin disorders, inflammatory skin disorders, autoimmune disease-related skin disorders and cancer-related skin disorders. In one embodiment, the compositions containing a combination of nicotinamide riboside and pterostilbene are prepared as oral formulations.

Claims (6)

1. A method of treating sunburn in a patient in need thereof comprising orally administering a combination of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene, wherein the therapeutically effective amount of nicotinamide riboside is 250 mg per day, the therapeutically effective amount of pterostilbene is 50 mg per day.

2. The method of claim 1 , wherein the therapeutically effective amount of nicotinamide riboside and the therapeutically effective amount of pterostilbene is administered in the same composition.

3. The method of claim 2 , wherein the composition comprises a pharmaceutically acceptable excipient.

4. The method of claim 3 , wherein the pharmaceutically acceptable excipient is selected from the group consisting of microcrystalline cellulose, hypromellose, vegetable magnesium stearate, olive oil, gelatin, glycerin, purified water, beeswax yellow, sunflower lecithin, silicon dioxide, titanium dioxide, F. D. & C Blue 1 and F. D. & C Red 4.

5. A method of treating lentigines or age spots in a patient in need thereof comprising orally administering a combination of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene, wherein the therapeutically effective amount of nicotinamide riboside is 250 mg per day, the therapeutically effective amount of pterostilbene is 50 mg per day.

6. A method of treating skin cancer in a patient in need thereof comprising orally administering a combination of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene, wherein the therapeutically effective amount of nicotinamide riboside is 250 mg per day, the therapeutically effective amount of pterostilbene is 50 mg per day.

Assignments (2)
SECURITY INTEREST Recorded Jan 29, 2024
From: ELYSIUM HEALTH, INC.
To: VENTURE LENDING & LEASING IX, INC.
Reel/Frame 066283/0775 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2022
From: MARCOTULLI, ERIC A.; ALMINANA, DANIEL A.; BOWEN, PAUL M.
To: ELYSIUM HEALTH, INC.
Reel/Frame 060744/0723 →
Continuity (3)
Continuation 15735066
Provisional Application 62173733 · Jun 10, 2015
Related Publication 20220362233A1 · Nov 17, 2022